騰盛博藥-B(02137.HK):很有信心公司療法很有效地中和Omicron
國家藥品監督管理局於本月8日應急批準騰盛博藥-B(02137.HK)旗下騰盛華創醫藥技術(北京)新冠病毒中和抗體聯合治療藥物安巴韋單抗注射液及羅米司韋單抗注射液註冊申請。騰盛博藥朱青接受媒體採訪時表示,安巴韋/羅米司韋單抗聯合療法是單次靜脈給藥,靜脈給藥血液抗體濃度會上升得非常快,在公司的劑量選擇下,可以很快地在幾個小時內達到300-400毫克/毫升的血液抗體濃度,這個數據說明在這樣的高濃度下,該療法在人的血清裏的最高抗體濃度可以達到針對Omicron變異病毒株IC50值的千倍和IC90值的百倍數量級。
朱青稱,公司有很大的信心,給藥的劑量是完全可以很有效地中和Omicron變異病毒株。
騰盛博藥收市報37.65元,升10.57%。成交額9,014萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.